June 30 (Reuters) - Liminal BioSciences Inc LMNL.TO :
* LIMINAL BIOSCIENCES PROVIDES GUIDANCE UPDATE ON CERTAIN EXPECTED KEY MILESTONES FOR 2020
* LIMINAL BIOSCIENCES - RE-SUBMISSION OF BLA WITH U.S. FDA FOR RYPLAZIM FOR CONGENITAL PLASMINOGEN DEFICIENCY TREATMENT ANTICIPATED TO BE FILED IN Q3
* LIMINAL BIOSCIENCES - MULTIPLE ASCENDING DOSE PHASE 1 CLINICAL STUDY OF FEZAGEPRAS EXPECTED TO BE INITIATED IN H2 2020